Examination of purported probes of human CYP2B6

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 165-179

  Ekins, Sean ^a   VandenBranden, Mark ^a   Ring, Barbara J ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

7 EFC; 7 HFC; CYP2B6; Selective inhibitors; Substrate specificaty

Indexed keywords

ALPHA NAPHTHOFLAVONE; CHLORAMPHENICOL; COUMARIN DERIVATIVE; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; ENZYME INHIBITOR; METHOXYCHLOR; NORMEPHENYTOIN; ORPHENADRINE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; B-LYMPHOCYTES; BENZOFLAVONES; BLOTTING, WESTERN; CELL LINE; CHLORAMPHENICOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COUMARINS; CYTOCHROME P-450 ENZYME SYSTEM; DITIOCARB; HUMANS; KINETICS; MICROSOMES; MICROSOMES, LIVER; MOLECULAR PROBES; ORPHENADRINE; OXIDOREDUCTASES, N-DEMETHYLATING; SUBSTRATE SPECIFICITY;

EID: 0030822760     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00001     Document Type: Article

References (68)

1. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994: 38, 131-137.
2. 1. Proc Natl Acad Sci 1990: 87, 4790-4793.
3. Ariyoshi N, Oguri K, Koga N, Yoshimura H, Funae Y. Metabolism of highly persistent PCB congener. 2,4,5,2′,4′,5′-hexachlorobiphenyl, by human CYP2B6. Biochem Biophys Res Comm 1995: 212, 455-460.
4. Bachmann K, Chu CA, Greear V. In vivo evidence that ethosuximide is a substrate for cytochrome P450IILA. Pharmacology 1992: 45, 121-128.
5. Baker MT, Olson MJ, Wang Y, Ronnenberg WC, Johnson JT, Brady AN. Isoflurane-chlorodifluorethane interaction in human liver microsomes. Drug Metab Dispos 1995: 23, 60-63.
6. Berkman CE, Park SB, Wrighton SA, Cashman JR. In vitro-In vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 1995: 50, 565-570.
7. Boobis AR, Edwards RJ, Adams DA, Davies DS. Dissecting the function of cytochrome P450. Br J Clin Pharmacol 1996: 42, 81-89.
8. Bourrié M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. J Pharmacol Exp Ther 1996: 277, 321-332.
9. Broly F, Libersa C, Lhermitte M, Bechtel P, Dupois B. Effect of quinidine on the dextromethophan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 1989: 28, 29-36.
10. Buters JTM, Schiller CD, Chou RC. A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Biochem Pharmacol 1993: 46, 1577-1584.
11. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993: 53, 5629-5637.
12. Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α-napthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 1994: 311, 437-442.
13. Chiba K, Kabayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes: Cosegregation with S-mephenytoin 4′-hydroxylation. Pharmacol Exp Ther 1993: 266, 52-59.
14. Code EL, CI, Crespi, Penman BW, Gonzalez FJ, Chang T, Waxman DJ. Immunochemical and enzymatic characterization of human hepatic levels of CYP2B6. ISSX Proc 1995: 8, 100.
15. Czerwinski M, McLemore TL, Gelboin HV, Gonzalez FJ. Quantification of CYP2B7, CYP4B1 and CYPOR messenger RNAs in normal human lung and lung tumors. Cancer Res 1994: 54, 1085-1091.
16. Dehal SS, Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Drug Metab Dispos 1994: 22, 937-946.
17. DeLuca JG, Dysart GR, Rasnick D, Bradley MO. A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog. Biochem Pharmacol 1988: 37, 1731-1739.
18. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalysing 4-hydroxylantipyrine, 3-hydroxymethyantipyrine, and norantipyrine formation. Clin Pharmacol Ther 1996: 59, 613-23.
19. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS, Skett P, Wolf CR. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 1992: 281, 359-368.
20. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994: 47, 173-182.
21. Guengerich FP, Kim D-H, Iwasaki M. Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991: 4, 168-179.
22. Heyn H, White, RB, Stevens JC. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996: 24, 948-953.
23. Hoult JRS, M Payá. Pharmacological and biochemical actions of simple coumarins: natural products with therapeutic potential. Gen Pharmacol 1996: 27, 713-722.
24. Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, Funae Y. Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Biochem Pharmacol 1996: 51, 1041-1050.
25. 1 by normal and tumorous liver tissue from Thailand. Carcinogenesis 1993: 14, 2613-2620.
26. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH. Human liver carbamazepine metabolism. Biochem Pharmacol 1994: 47, 1969-1979.
27. Koyama E, Chiba K, Tani M, Ishizaki T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996: 278, 21-30.
28. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED. Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995: 23, 490-496.
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature 1970: 227, 680-685.
30. Lewis AD, Walker C, Morecroft I, Henderson C, Wolf CR. Role of human NADPH: cytochrome P-450 CYP2B gene family in the metabolism of the anticancer bioreductive drug tirapazamine (WIN 59075: SR4233). Proc Am Assoc Cancer Res 1995: 36, 3581.
31. McCracken NW, Cholerton S, Idle JR. Cotinine formation by cDNA-expressed human cytochromes P450. Med Sci Res 1992: 20, 877-878.
32. Miles JS, Spurr NK, Gough AC, Jowett T, McLaren AW, Brook JD, Wolf CR. A novel human cytochrome P450 gene (P450IIB):chromosomal localization and evidence for alternative splicing. Nucleic Acid Res 1988: 16, 5783-5795.
33. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez FJ, Guengerich FP, Shimada T. Characterisation of cytochrome P-450 2B6 in human liver microsomes. Drug Metab Dispos 1993: 21, 1048-1056.
34. Murray M, Reidy GF. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 1990: 42, 82-101.
35. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Vainio H, Aoyama T. Characterisation of human cytochrome P450 isozymes responsible for styrene metabolism. In: Sorsa M, Peltonen K, Vainio H, Hemminki K, eds. Butadiene and styrene: Assessment of health hazards. Lyon, IARC Scientific Publications No 127, 1993: 101-108.
36. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 1994: 7, 891-896.
37. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995: 23, 154-158.
38. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Spicificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996: 26, 681-693.
39. Penman BW, Chen L, Gelboin HV, Gonzalez FJ and Crespi CL. Development of a human lymphoblastoid cell line constitutively expressing human CYPIA1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis 1994: 15, 1931-1937.
40. Pessayre D, Tinel M, Larrey D, Colbert B, Funck-Bretano C, Babany G. Inactivation of cytochrome P-450 by a troleandomycin metabolite: Protective role of glutathione. J Pharmacol Exp Ther 1983: 224, 685-691.
41. 1. Cancer Res Toxicol 1992: 5, 202-210.
42. Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: In vitro and in vivo evidence for isozyme-spicific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 1989: 35, 736-743.
43. Ring BJ, Catlow J, Lindsey TJ, Gillespie T, Roskos LK, Cerimile BJ, Swanson SP, Hamman MA, Wrighton SA. Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996: 276, 658-666.
44. Roos PH, Mahnke A. Metabolite complex formation of orphenadrine with cytochrome P450. Biochem Pharmacol 1996: 52, 73-84.
45. 6-benzylguanine. Biochem Pharmacol 1995: 50, 1385-1389.
46. Schmider J, Greenblatt DJ, Harmatz JS, Shader RI. Enzyme kinetic modeling as a tool to analyze the behaviour of cytochrome P450 catalyzed reactions: application to amitryptyline N-demethylation. Br J Clin Pharmacol 1996a: 41, 593-604.
47. Schmider JS, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies. Pharmacology 1996b: 52, 125-134.
48. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-napthoflavone. Mol Pharmacol 1988: 33, 493-499.
49. Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state system. New York: Wiley & Sons Inc, 1993.
50. Sesardic D, Boobis AR, Murray BP, Segura J, De La Torre R, Davies DS. Furafylline is a potent and selective inhibitor of cytochrome P450IA2. Br J Clin Pharmacol 1991: 29, 651-662.
51. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemical: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
52. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, Korzekwa KR. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994: 33, 6450-6455.
53. Stohs SJ, Grafström RC, Burke MD, Moldeus PW, Orrenius SG. The isolation of rat intestinal microsomes with stable cytochrome P-450 and their metabolism of benzo(α)pyrene. Arch Biochem Biophys 1976: 177, 105-116.
54. 3H]methoxychlor as a probe for liver microsomal CYP2B activity: potential for in vivo CYP2B assay. Anal Biochem 1996: 233, 100-107.
55. Styles JA, Davies A, Lim CK, DeMatteis F, Stanley LA, White INH, Yuan Z-X, Smith LL. Genotoxicity of tamoxifen, tamoxifen epoxide and tormifene in human lymphblastoid cells containing human cytochrome P450s. Carcinognesis 1994: 15, 5-9.
56. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez FJ, Miners JO. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992: 2, 173-183.
57. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheet: procedure and some applications. Proc Natl Acad Sci 1979: 76, 4350-4354.
58. 1 by bacterial recombinant human cytochrome P450 enzymes. Chem Res Toxicol 1995: 8, 218-225.
59. VandenBranden M, Ring BJ, Binkley S, Wrighton SA. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996: 6, 81-91.
60. van der Hoeven TA Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974: 249, 6302-6310.
61. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991: 175, 1112-1118.
62. Wormhoudt LW, Ploemen JHTM, deWaziers I, Commandeur JNM, Beaune PH, van Bladeren PJ and Vermeulen NPE. Interindividual variability in the oxidation of 1,2-dibromoethane: use of heterologously expressed human cytochrome P450 and human liver microsomes. Chem Biol Interactions 1996: 101, 175-192.
63. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992: 22, 1-21.
64. Wrighton SA, VandenBranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 1993: 25, 454-484.
65. Wrighton SA, Ring BJ, VandenBranden M. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies. Toxicologic Pathology 1995: 23, 199-208.
66. Yamano S, Nhamburo PT, Aoyama T, Meyer UA, Inaba T, Kalow W, Gelboin HV, McBride OW, Gonzalez FJ. cDNA cloning and sequence and cDNA-directed expression of human P450IIB1: Identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989: 28, 7340-7348.
67. Yamazaki H, Inoue K, Mimura M, Oda Y, Guengerich FP, Shimada T, 7-ethoxycoumarin O-deethylation catalyzed by cytochromes P4501A2 and 2E1 in human liver microsomes. Biochem Pharmacol 1996: 51, 313-319.
68. Yun C-H, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991: 40, 679-685.